Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 23;115(19):E4473–E4482. doi: 10.1073/pnas.1802354115

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 the Author(s). Published by PNAS.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

PMC Copyright notice

Fig. 4. — Validation of candidate prostate cancer subtype-specific cell-surface antigens. (A) Immunoblot analysis of select PrAd (LNCaP, CWR22Rv1, and DU145) and NEPC (NCI-H660, MSKCC EF1, and LASCPC-01) cell lines as well as benign human tissues (brain, heart, kidney, liver, and lung) with antibodies against STEAP1, FXYD3, FOLH1, NCAM1, SNAP25, CEACAM5, and GAPDH as a loading control. (B) Human prostate tissue (Hu prostate) or prostate cancer cell line (LNCaP, CWR22Rv1, NCI-H660, MSKCC EF1, and LASCPC-01) xenograft sections after immunohistochemical staining with antibodies for the candidate antigens from A. (Scale bar, 25 µm.) (C) Flow cytometry histogram plots of the PrAd cell line LNCaP and the NEPC cell line NCI-H660 stained with antibodies against STEAP1, FXYD3, NCAM1, and CEACAM5.